Literature DB >> 14624185

Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial.

Darlene H Moak1, Raymond F Anton, Patricia K Latham, Konstantin E Voronin, Randolph L Waid, Ramon Durazo-Arvizu.   

Abstract

Alcoholism and depression are common disorders that frequently co-occur in the same individual. Selective serotonin reuptake inhibitors (SSRIs) are effective in the treatment of depression and also had decreased drinking in some studies of heavy drinkers and alcoholics. The reported effect of serotonergic medications on alcohol intake in depressed alcoholics has not been consistent. Most previous studies have not investigated the use of an SSRI in the context of cognitive behavioral therapy (CBT), a known efficacious treatment of both alcoholism and depression. The study presented here was a randomized placebo-controlled 12-week trial of sertraline combined with individual CBT focused on both alcoholism relapse prevention and depressive symptoms. Subjects were 82 currently depressed, actively drinking alcohol-dependent individuals. Subjects had either primary (independent) major depression (70 subjects) or substance-induced mood disorder and at least 1 first-degree relative (parent, sibling, or child) with an affective disorder (12 subjects). Depression and alcohol consumption outcomes were measured weekly over 12 weeks. Sertraline was well tolerated and all subjects had decreases in both depression and alcohol use during the study compared with baseline. Subjects who received sertraline had fewer drinks per drinking day than subjects who received placebo, but other drinking outcomes were not different between the 2 treatment groups. Treatment with sertraline was associated with less depression at the end of treatment in female subjects compared with female subjects who received placebo. Less drinking during the study was associated with improved depression outcome. The findings in this study suggest that sertraline, compared with placebo, may provide some modest benefit in terms of drinking outcome and also may lead to improved depression in female alcohol-dependent subjects. Additionally, alcohol relapse prevention CBT, delivered according to manual guidelines with modifications that provide specific attention to depression, appeared to be of benefit to subjects, although this interpretation is limited by the design of the study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624185     DOI: 10.1097/01.jcp.0000095346.32154.41

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  28 in total

1.  The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.

Authors:  Aron N Starosta; Robert F Leeman; Joseph R Volpicelli
Journal:  J Psychiatr Pract       Date:  2006-03       Impact factor: 1.325

Review 2.  Treatment options for sleep disturbances during alcohol recovery.

Authors:  J Todd Arnedt; Deirdre A Conroy; Kirk J Brower
Journal:  J Addict Dis       Date:  2007

3.  Combining motivational interviewing with compliance enhancement therapy (MI-CET): development and preliminary evaluation of a new, manual-guided psychosocial adjunct to alcohol-dependence pharmacotherapy.

Authors:  Jaimee L Heffner; Giao Q Tran; Candace S Johnson; Suzan Winders Barrett; Thomas J Blom; Rachel D Thompson; Robert M Anthenelli
Journal:  J Stud Alcohol Drugs       Date:  2010-01       Impact factor: 2.582

4.  Meta-analysis of supplemental treatment for depressive and anxiety disorders in patients being treated for alcohol dependence.

Authors:  Jennifer D J Hobbs; Matt G Kushner; Susanne S Lee; Sean M Reardon; Eric W Maurer
Journal:  Am J Addict       Date:  2011-05-31

Review 5.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 6.  Medical treatment of alcohol dependence: a systematic review.

Authors:  Peter M Miller; Sarah W Book; Scott H Stewart
Journal:  Int J Psychiatry Med       Date:  2011       Impact factor: 1.210

7.  Psychiatric comorbidities in alcohol use disorder.

Authors:  Alvaro Castillo-Carniglia; Katherine M Keyes; Deborah S Hasin; Magdalena Cerdá
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

Review 8.  Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders.

Authors:  Benjamin I Goldstein; Artemis Diamantouros; Ayal Schaffer; Claudio A Naranjo
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 9.  A review of treatment options for co-occurring methamphetamine use disorders and depression.

Authors:  Tracy L Hellem; Kelly J Lundberg; Perry F Renshaw
Journal:  J Addict Nurs       Date:  2015 Jan-Mar       Impact factor: 1.476

10.  Course of late-life depression with alcoholism following combination therapy.

Authors:  Raman Gopalakrishnan; Jennifer Ross; Charles O'Brien; David Oslin
Journal:  J Stud Alcohol Drugs       Date:  2009-03       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.